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A natural history study of X-linked
myotubular myopathy
ABSTRACT
Objective: To define the natural history of X-linked myotubular myopathy (MTM).
Methods: We performed a cross-sectional study that included an online survey (n 5 35) and
a prospective, 1-year longitudinal investigation using a phone survey (n 5 33).
Results: We ascertained data from 50 male patients with MTM and performed longitudinal as-
sessments on 33 affected individuals. Consistent with existing knowledge, we found that MTM
is a disorder associated with extensive morbidities, including wheelchair (86.7% nonambulant)
and ventilator (75% requiring .16 hours of support) dependence. However, unlike previous
reports and despite the high burden of disease, mortality was lower than anticipated (approximate
rate 10%/y). Seventy-six percent of patients with MTM enrolled (mean age 10 years 11 months)
were alive at the end of the study. Nearly all deaths in the study were associated with respiratory
failure. In addition, the disease course was more stable than expected, with few adverse events
reported during the prospective survey. Few non–muscle-related morbidities were identified,
although an unexpectedly high incidence of learning disability (43%) was noted. Conversely, MTM
was associated with substantial burdens on patient and caregiver daily living, reflected by missed
days of school and lost workdays.
Conclusions: MTM is one of the most severe neuromuscular disorders, with affected individuals
requiring extensive mechanical interventions for survival. However, among study participants,
the disease course was more stable than predicted, with more individuals surviving infancy and
early childhood. These data reflect the disease burden of MTM but offer hope in terms of future
therapeutic intervention. Neurology® 2017;89:1355–1364
GLOSSARY
MTM 5 myotubular myopathy; MTM1 5 myotubularin; PES 5 perinatal evaluation score.
X-linked myotubular myopathy (MTM) is a neuromuscular disorder caused by mutations in the
myotubularin (MTM1) gene.1 It is a rare condition (estimated at 1:50,000 male births) asso-
ciated with substantial morbidities and early mortality.2 At present, there are no treatments or
disease-modifying therapies. However, several therapeutic strategies, including gene therapy,3
enzyme replacement therapy,4 dynamin-2 modulation,5 and PIK3C2B inhibition,6 are showing
promise in preclinical studies.
A key barrier to clinical translation for MTM is the lack of natural history data. Two previous
studies examining clinical characteristics were performed in 1999 and 2002,7,8 and each iden-
tified considerable disease morbidities and extremely high mortality. The literature also includes
several case reports9–11 and a congenital myopathy cohort study (including 8 MTM cases),11
each corroborating the severe weakness and early mortality of patients with MTM. There
From the Division of Neurology (K.A., E.T., C.-T.N., J.J.D.) and Program for Genetics and Genome Biology (E.T., J.J.D.), Hospital for Sick
Children; Departments of Paediatrics (K.A., J.J.D.), Computer Science (M.G.), and Molecular Genetics (J.J.D.), University of Toronto, Ontario,
Canada; Cure CMD (R.A., S.d.C., A.R.), Torrance, CA; Autodesk Research (M.G.), Toronto, Ontario, Canada; Kaiser SCPMG (A.R.), Torrance,
CA; Physical Medicine and Rehabilitation (J.H.), University of Michigan, Ann Arbor; and Division of Genetics and Genomics (A.H.B.), The
Manton Center for Orphan Disease Research, Boston Children’s Hospital, Harvard Medical School, MA.
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
The Article Processing Charge was funded by the authors.
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC
BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used
commercially without permission from the journal.
Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology 1355
Figure 1 Survival and burden of disease in an MTM cohort
(A) Survival of participants over the course of the study. For those who died, age and cause of death are summarized in the table to the right of the graph.
Twelve of 50 patients in our cohort were deceased, and the average age at death was 6 years 10 months. Note that 3 died during the longitudinal study,
including 1 individual who died 2 months after survey completion. (B) Burden of disease (respiratory, feeding, and ambulation support requirements).
Continued
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remains, however, a critical lack of knowledge
of the MTM disease process, limiting the abil-
ity to develop outcome measures and hinder-
ing current clinical care, particularly as it
relates to anticipatory guidance and disease
prognostication. At present, MTM care is
based on generalized practice guidelines estab-
lished for all congenital myopathies.12
To address the need for natural history
data, we performed a cross-sectional plus pro-
spective, longitudinal study of MTM. We
found that patients with MTM have severe
morbidities, including wheelchair, ventilator,
and feeding tube dependence, but markedly
longer survival than previously reported. We
discovered that the disease course is relatively
stable, although with sizeable impact on daily
activities for patients and caregivers. In total,
we identified important parameters that will
guide clinical care and future clinical trials.
METHODS Study participants, data collection, protocol
approvals, registrations, and patient consent. Our cohort
included male patients with confirmedMTM1mutation or mus-
cle biopsy consistent with MTM plus family history consistent
with X-linked inheritance. Patients were recruited at MTM fam-
ily conferences and through the Cure CMD registry. Medical
records were obtained with a signed Authorization to Request
Medical Records. Written consent was obtained, either from an
English-speaking parent/guardian or from an English-speaking
decisionally competent affected male patient .18 years of age.
The cross-sectional and longitudinal (NCT01840657) studies
were reviewed and approved by the University of Michigan Insti-
tutional Review Board (HUM00032624 and HUM00066029).
Ethics approval was obtained before study initiation. All partic-
ipants were assigned deidentified numbers.
Cross-sectional data were collected via parent-reported sur-
veys with the Qualtrics system (Provo, UT) (n 5 35). Surveys
were administered at enrollment and at a follow-up date when
available. Data for the 1-year prospective study were collected
from 2 sources: medical records and monthly telephone inter-
views recorded on a paper survey (n 5 33). Additional details
are provided in the e-Methods (at Neurology.org).
RESULTS Cohort characteristics. Our cohort
included 50 individuals with MTM: 35 in the
cross-sectional study and 33 in the longitudinal
study; 18 individuals participated in both studies,
including 4 sibling pairs. Ages ranged from 1 day to
42 years 4 months, with a median age of 8 years 4
months and average age of 10 years 11 months
(figure 1A and table e-1).
Survival. Data were ascertained for 12 deceased pa-
tients with MTM (figure 1A). Age of death ranged
from 1 day to 25 years 4 months, with an average age
at death of 6 years 10 months and mean survival of 12
years 2 months. Ten of 12 patients died of respiratory
complications, with nonrespiratory deaths caused by
cardiac arrest (likely precipitated by pseudomonas
infection) and fatal hemorrhage at an indwelling cath-
eter site. There were 3 deaths among the 33 individ-
uals who participated in the 1-year prospective study.
Overall disease burden. To evaluate MTM comorbid-
ities, we looked at 3 parameters: wheelchair, feeding
tube, and ventilator dependence (figure 1B). Forty-
eight of 50 individuals required at least 1 of these
interventions, and 37 required all 3, reflecting the
high degree of technology dependence in MTM.
Motor functional status. Forty-five of 50 participants
were .2 years of age and thus considered of ambu-
latory age. Of this group, only 6 (13.3%) were ambu-
lant. Seven of 33 in the longitudinal study had
previously walked but lost the ability before survey
initiation. For nonambulant individuals, current
maximum motor function was as follows: 1 patients
could stand without support for .10 seconds and
take steps with assistance; 24 patients could sit with-
out support for .10 seconds; and 16 individuals
could not sit or stand independently (figure 1D).
There were impairments in other motor skills as well:
9 of 33 patients could feed themselves, 12 of 33 could
comb their hair, 14 of 47 could brush their teeth, 5 of
33 could button clothing, and 29 of 33 could pick up
small objects. Twelve of 32 patients lost 1 or more of
these abilities over time (figure e-1).
Twelve individuals participated in a physical
examination, with 5 having 2 examinations separated
by 12 months. Muscle weakness was diffuse in all,
including striking facial musculature involvement
and complete or near-complete ophthalmoparesis.
In the 9 nonambulant individuals, extremity weak-
ness was severe. Three had no antigravity strength,
while 4 achieved antigravity strength only in distal
muscles. The remaining 2 had movements against
gravity and with some resistance. Overall, examination
features were consistent with previous reports,2,9,11
Figure 1 legend, continued:
Breakdown of technology support required, including wheelchair dependence, feeding tube, and ventilation. Forty-eight of 50 patients with MTM had some
technology dependence, and 37 of 48 were wheelchair, ventilator, and tube feed dependent. (C) Change in respiratory status during the 1-year longitudinal
survey (listed as percent of the total cohort, n5 33). The majority of individuals had either no change or small fluctuations in support. Small fluctuations were
defined as 1 or 2 increases or decreases in time on ventilation that lasted ,3 months. Frequent changes were defined as $3 periods (#3 months) of
increased or decreased ventilator setting requirements. Changes in time needing ventilation sustained for at least 4 months are indicated as increased
requirements or sustained improvement. (D) Breakdown of the extent of feeding support, respiratory support, and highest motor function at the time of
survey completion. G-tube 5 gastrostomy tube; MTM 5 myotubular myopathy.
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although we additionally observed neck flexor
weakness and the combination of joint hypermo-
bility plus joint contractures in most individuals
(figure e-2).
Quantitative testing included timed 10-m walk (3
of 12 individuals were able perform), the Hammer-
smith scale for children with spinal muscular atro-
phy,13 and repetitive nerve stimulation (table e-2).
For the Hammersmith scale, the mean score was 11
and the median was 3, with scores largely segregated
into 2 groups: ,10 of 40 (9 of 12 patients) and.35
of 40 (3 of 12 patients). Repetitive nerve stimulation
studies were technically limited because of submaxi-
mal stimuli in each case; however, no individual dem-
onstrated electrodecrement. No appreciable
differences in examination or quantitative testing
were noted in the 5 individuals who underwent repeat
evaluation.
Respiratory status. At the time of survey completion,
48 of 50 individuals required some element of respira-
tory support, and 38 of 50 had tracheostomies in active
use. Thirty-nine individuals used support $8 hours
per day, with 33 requiring .16 hours of ventilation.
We investigated respiratory variability over the
prospective 1-year analysis (n 5 33) (figure 1C). In
general, patients remained stable, with 8 having no
change in ventilation requirements and 16 experienc-
ing only minor fluctuations, related primarily to
increased ventilator dependence during illness or in
the immediate postoperative period (figure e-3).
Three individuals had modest, sustained functional
improvements lasting .3 months, while 6 required
increased support.
Other medical problems and surgeries. A full review of
medical comorbidities is presented at http://
phenostacks.org/AmburgeyMTM (figures e-2 and
e-4) and summarized in table 1. Scoliosis was the
most common comorbidity, occurring in 72% of
individuals (mean age at presentation 31.5 months).
In 13 cases, scoliosis worsened over time, and 10
patients reported rapid change (mean age for change
10 years 1 month) (figure e-1). Twelve individuals
used spinal bracing, and 9 underwent scoliosis sur-
gery. Of patients who developed scoliosis before 5
years of age, 8 of 22 required scoliosis surgery, as
opposed to 1 of 7 with later onset.
Other commonly encountered problems were acid
reflux, constipation, and bone fractures. Hearing dif-
ficulties were surprisingly reported in 15 of 33 and
vision difficulties in 16 of 33. Chronic/recurrent otitis
media occurred frequently, as did respiratory infec-
tions. Cardiac involvement was rare, with only 1
report of cardiomyopathy, 2 reports of hypertension,
and 6 reports of tachycardia. Three individuals were
Table 1 Nonmuscular comorbidities in X-linked myotubular myopathy
Comorbidity by system
Patients
experiencing, n
Patients
surveyed, n Percentage
Ear/nose/throat
Ear infection 10 49 20.4
Ear issues (fluid, surgery) 14 49 28.6
Neurologic
Seizures 2 49 4
Cardiac
Arrhythmias 7 49 14.3
Structural (hole) 3 34 8.8
Structural (ventricle thickening) 1 49 2
Structural (enlarged) 1 34 3
Cardiomyopathy 1 34 3
Mild systolic dysfunction 1 49 2
Pulmonary hypertension 1 34 3
Respiratory
Respiratory, chest, lung infections 26 49 53.1
Respiratory distress 14 49 28.6
Dyspnea, shortness of breath 10 49 20.4
Lung collapse 8 49 16.3
Ventilator/tracheostomy issues
(mechanical, mucous plugs)
12 49 24.5
Gastrointestinal
Pyloric stenosis 2 34 5.9
Gastrointestinal problems 18 49 36.7
Constipation 23 49 46.9
Gastrostomy-tube issues (leak, rash,
position)
5 49 10.2
Gallstones 3 34 8.8
Skeletal
Pectus excavatum 8 34 23.5
Pectus carinatum 3 34 8.8
Broken bones 4 49 8.2
Scoliosis 36 48 75
Liver
Abnormal liver enzymes/function
tests
11 49 22.5
Enlarged liver 4 34 11.8
Jaundice 5 34 14.7
Liver bleed/hemorrhage 2 34 5.9
Kidney
Kidney issues (hyponatremia, distal tube
damage, enlarged ureter)
3 34 8.8
Kidney stones 5 49 10.2
Nephrocalcinosis 1 34 3
Genitourinary
Urinary tract infection 3 49 6
Undescended testes 25 34 73.5
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reported to have septal defects at birth, which is
slightly higher than the general population risk (esti-
mated at 1:2000). Liver involvement, including the
feared complication of hepatic peliosis, was uncom-
mon. We recorded 2 instances of liver hemorrhage
(table 1 and figure e-1); neither was confirmed as
related to peliosis (although it was suspected), and
neither was fatal.
Twelve of 28 individuals were documented to
have learning disability. In those who had formal neu-
ropsychological testing (n 5 10), 8 had abnormal
studies, and 6 had impairments in all learning areas.
Figure 2 Perinatal evaluation score (PES) and neonatal respiratory support in relation to patient outcome
(A) Breakdown of PES and patient outcome. PES was defined by McEntagart et al.7 Individuals with scores for at least 4 of the 6 PES factors were included.
Most individuals in our cohort were in the severe ormoderate categories for PES (PES,3 of 6 or,50%). There was no obvious correlation between PES and
need for future respiratory support and survival. PESwas determined by 6 factors: delivery (normal5 1, abnormal5 0), fetal movement (normal5 1, weak or
absent 5 0), polyhydramnios (no 5 1, yes 5 0), tendon reflexes at birth (present 5 1, absent 5 0), joint contractures or club feet (no 5 1, yes 5 0), and
intubation at birth (no 5 1, yes 5 0). All 34 had scores (0 or 1) for at least 4 of 6 factors. (B) Flow diagram of respiratory requirement at birth and patient
outcome. Modeled after the flow diagram in McEntagart et al.7 Sufficient perinatal data were available for 35 individuals with MTM in the study. Note that
essentially all individuals who required respiratory support at birth went on to need it after the neonatal period. While a small sample size, 2 of 3 who did not
require breathing support at birth were ventilator free at study completion (ages 2 years 2 months, 32 years 10 months, and 42 years 4 months). XLMTM5
X-linked myotubular myopathy.
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Only 1 patient carried a formal diagnosis of intellec-
tual disability. In terms of other neurobehavioral
diagnoses, only 1 of 26 had attention-deficit/
hyperactivity disorder. Speech abnormalities paral-
leled learning disabilities. The mean age for first
words was 17 months and for first sentences was 29
months. Hypophonic voice was common (16 of 33),
and 12 of 33 had speech articulation difficulties.
Prenatal and birth history. Consistent with previous re-
ports, a high degree of prenatal and perinatal disease
was noted.7 Twelve of 32 mothers reported decreased
fetal movements, and 19 of 33 pregnancies were com-
plicated by polyhydramnios. Prematurity (,36
weeks) was noted in 12 of 34 births. Forty-three of
48 patients required respiratory support at birth.
Hypotonia was uniformly noted. Congenital con-
tractures were relatively common (observed in 10 of
28), although only 1 dislocation (hip) was noted.
Diagnosis was achieved in all but 1 patient during the
neonatal period, accomplished by muscle biopsy in
24 of 33 and by gene testing in the remainder.
In the 2002 genotype–phenotype study,7 the au-
thors used a perinatal evaluation score (PES; deter-
mined by 6 perinatal factors) as a means of grading
severity at birth and correlating severity with future
outcomes. We calculated PES for our cohort (figure
2A). We observed high neonatal severity (low PES) in
nearly all cases, as well as a general correlation
between PES and eventual respiratory requirement,
with individuals scoring in the 0% to 25% category
requiring .16 hours of support. The PES poorly
correlated with survival, with a similar distribution of
death across all score ranges. Of note, the most mildly
affected patients in our cohort had on average lower
PES (more severe) than the previous study (0.5 vs 0.8
in the previous study).
We also looked at duration of neonatal breathing
support as a predictor of disease outcomes. Twenty-
nine of 32 patients required respiratory support at
birth. All 3 individuals not requiring neonatal respira-
tory support were alive at the time of survey (figure
2B), as opposed to 9 of 29 dead in the group requir-
ing it. There was no obvious correlation between the
length of respiratory support and outcomes; equal
percentages of individuals currently needing ventila-
tor support were in the group requiring,1 week and
the group needing .30 days of neonatal support.
Genotype–phenotype correlation. MTM1 genetic test-
ing reports were available for 35 participants, repre-
senting 27 unique mutations and 5 recurrent
mutations.14 Mutations were located throughout the
gene with no obvious hotspots and no clear clustering
to known functional domains (figure 3).15 We exam-
ined clinical phenotype in comparison to mutation
subtype (figure e-5). Sixteen of 17 individuals with
nonsense mutations were in the severely impaired
category (nonambulant plus mechanical respiratory
support). The 1 individual with milder presentation
achieved the ability to walk and did not require ven-
tilator support; however, he died at the age of 2.5
Figure 3 Genotype–phenotype correlations
Genetic testing results were available for 35 individuals. Twenty-seven unique mutations were identified. For genotype–phenotype assessment, mutations
were categorized as nonsense (n5 17), missense (n5 10), or splice site (n5 8). Of note, 1 recurrent missense mutation (R69C in the PH-GRAM domain) has
been shown to alter splicing (Pierson et al.14). (A) Mutation type and location. Mutations inMTM1were found throughout the gene, and there was no obvious
clustering in sections of theMTM1 gene coding for the known functional domains. Protein domain locations were defined by Laporte et al.15 (B) Mutation type
and location in relationship to respiratory requirement. Because nearly all individuals required ventilatory support, there was no clear correlation between
ventilation and mutation type, although a higher proportion of individuals with missense mutations did not need invasive support (4 of 10 missense on
noninvasive support vs 0 of 17 nonsense and 1 of 8 splice site). (C) Mutation location and motor function. Other than 1 individual with a nonsense mutation,
only individuals with missense mutations achieved the ability to ambulate independently (3 of 10).
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years. Three of 10 individuals with missense muta-
tions were ambulatory, and 4 of 10 required only
noninvasive respiratory support. There was more
variability among the 8 individuals with splice-site
mutations, with 75% requiring a ventilator, 13%
requiring noninvasive support, and 13% requiring no
breathing support. Of note, scoliosis and feeding tube
dependence were common across all genotypes, and
survival did not obviously correlate with mutation
type. Overall, our mutational analyses matched pre-
vious genotype–phenotype studies.7,16
Prospective evaluation of disease characteristics. We ob-
tained prospective data for a 1-year time period (n 5
33, age range 1 year 4 months–26 years, mean age 11
years). Three individuals died during the course of the
study (figure 1A). Outside of these obviously
severe events, the disease course was relatively stable
(figure 1C).
We focused on 3 areas that reflected disease bur-
den for patients and families (figure 4 and table
e-3). The first was hospital visits. There were 38
emergency room visits or an average of 1.15 annual
visits per patient. Fourteen of 33 had 1 or 2 visits, 1 of
33 had 3 visits, and 1 of 33 had 5 visits, while 16 of
33 had none. The most common reasons for emer-
gency room visits were infection (10 of 38), fever (8
of 38), and equipment issues (7 of 38). Of note, from
our retrospective data (n 5 30), the average number
of emergency room visits per year during the first 2
Figure 4 Hospitalizations and surgeries during a 1-year prospective study of myotubular myopathy
We tracked hospital visits (ER and admissions) and surgeries during our 1-year prospective analysis. Twenty-four of 33 individuals in the study required at
least 1 of these services (pie chart, top left). There were 38 ER visits (pie chart, top right, listed by chief complaint), with fever and infection themost common
reasons. Infections included pneumonia, pseudomonas, enterovirus, and rhinovirus. aRespiratory issues included respiratory distress, lung collapse, and high
CO2 levels. bEquipment issues included ventilator malfunction, mucous plugs, and leaky gastrostomy tubes. cOther reasons for ER visits included drug
allergy, power chair accident, postsurgical hip pain, and inability to urinate. There were 13 emergent hospitalizations (i.e., not scheduled or elective
admissions), with infection the overwhelmingly most common reason for admission (pie chart, bottom right). There were 27 elective surgical procedures
reported, with ear tube placement (i.e., myringotomy tube placement) the most common surgery. ER 5 emergency room.
Neurology 89 September 26, 2017 1361
years of life was 2.53 per patient. There were 13
emergent hospitalizations, for an average of 0.39 per
individual. Infection (7 of 13) and fever (2 of 13)
were the most common reasons for hospitalization.
In addition, there were 27 elective procedures (0.82
per patient). Myringotomy tube placement was the
most common surgery (7 of 27), followed by spinal
surgery (4 of 27). Nine of 33 patients avoided hospi-
tal encounters; of the 24 patients requiring at least 1
hospital visit, 6 experienced almost half of all events
(36 of 78).
Next, we examined number of school days missed
(n 5 21 school-aged individuals, with 14 attending
traditional school and 7 home school). The total
number of missed days was 476, an average of 22.7
per eligible patient. This was not distributed uni-
formly; 4 patients missed .50 days (range 53–91,
all secondary to illness or postsurgical recovery).
Forty-eight percent of patients with MTM missed
.12 days of school compared to the US average of
6% overall and 14.9% for children with special care
needs (www.qualitymeasures.ahrq.gov/summaries/
summary/47477).
The third parameter measured was number of
workdays missed. Four hundred thirteen days of work
were missed, averaging 1 d/mo per family (12.52 d/y).
This contrasts with the US average, which is 4 d/y lost
to childcare. The most common reasons for missing
work were lack of nursing coverage and medical
appointments.
DISCUSSION This comprehensive MTM natural
history study enables new assessment of clinical care
parameters, improved prognostication, and evalua-
tion of potential clinical trial outcome measures.
Perhaps our most important observation is that
survival in MTM is increased over previous reports.
We report deaths in 12 of 50 participants, with an
average age of 6 years 10 months and 83% of deaths
occurring before age 9. This contrasts with previous
studies describing up to 50% of patients dying in
the first year of life and 90% dying by age 10.2,7 This
was not due to lack of severity in our cohort because
88% were nonambulant and required .8 hours of
ventilatory support. One caveat is that our study
potentially underascertained cases associated with
neonatal death (and MTM infants in general) because
parents in this setting may be less likely to participate
in a study such as ours. Two other considerations are
that our cohort is composed of patients in North
America (where care decisions for critically ill neo-
nates can be different from those in other continents)
and that neuromuscular respiratory care has advanced
compared to 2002. True determination of survival in
MTM requires a prospective study in which all pa-
tients are enrolled and followed up from diagnosis.
Our data predict an approximate annual death rate
in patients with MTM of 10%. This agrees with the
general examination of our full cohort, in which we
observed a linear death rate in the first decade of life,
although with a relative increase in infants. In the sec-
ond decade and beyond, however, the death rate ap-
pears lower, although our numbers are comparatively
small for these age ranges.
The improved survival in our MTM cohort does
not reflect a reduction in overall disease severity. Only
2 individuals had no technology requirements, and
most (75%) needed invasive care in essentially all do-
mains. This high disease burden was echoed by a size-
able effect on school and work life; students with
MTM missed nearly 1 month of school on average,
and families missed at least 1 day of work per month.
Of note, despite the fact that most patients with
MTM share a similar extent of disability, the effect
on school/work was not uniformly distributed, with
a few individuals missing the majority of school days.
Additional investigation is needed to understand why
these differences were observed, although most fre-
quently the long school absences were associated with
medical complications.
A second important observation is that the disease
course appears relatively stable, as reflected by the low
rate of emergency room and hospital visits. This was
surprising to us, given that most individuals with
MTM have extensive respiratory requirements and
are considered medically fragile. One potential expla-
nation is the skill (and resources) of parents and care-
givers in terms of managing respiratory difficulties,
a factor that may be skewed in our cohort (which
relied on families who could attend family conferen-
ces or participate in monthly phone surveys).
Another important observation is that the inci-
dence of “nonmuscle” comorbidities was lower than
predicted by previous reports.8 In particular, we
observed only a single instance of suspected hepatic
peliosis in our retrospective cohort (with 1 additional
incident of liver hemorrhage during the prospective
survey) and no other severe medical issues not related
to infection or respiratory exacerbation. While there is
little doubt that nonmuscle problems occur in MTM,
our data suggest that they are relatively uncommon.
As with survival, determining the true incidence of
issues such as hepatic peliosis requires a long-term
prospective longitudinal study. In addition, because
these events may be age dependent, fully understand-
ing their prevalence may need evaluation of a larger
cohort of older patients.
One surprising morbidity was learning impair-
ment, with 43% of patients reported to have a learn-
ing disability. A contributor to this problem is likely
impaired speech mechanics and the potentially high
risk for perinatal hypoxia. Whether there additionally
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is a primary cognitive component to the disease is
harder to know. Myotubularin is expressed not only
in muscle but also in many tissues, including the
brain. However, no CNS abnormalities have been re-
ported in MTM animal models, although they have
not been rigorously investigated. Future study is nec-
essary to sort out this potentially important issue.
Our other major goal was to identify disease char-
acteristics suitable for application as outcome meas-
ures. We achieved this in part, but primarily by
identifying characteristics unlikely to be suitable for
clinical trials. For example, the Hammersmith scale
gave both floor and ceiling effects, with the cohort
basically divided between extremes of very low and
very high scores. Alternative motor scales such as
the Hammersmith Function Motor Scale Expanded
(modified for ambulant patients with spinal muscular
atrophy) or the Motor Functional Measure 20/32
(used for many neuromuscular diseases and enables
separation of skills into domains) could provide better
discrimination in MTM and thus be more appropri-
ate for future studies. In addition, events such as
emergency room visits and hospitalizations were
lower than expected and thus likely not suitable; the
same could be said for survival. In contrast, respira-
tory status appears promising as an outcome measure.
Most patients with MTM require some level of inter-
vention that is relatively unchanging over a 1-year
period. Our data could thus enable estimation of sam-
ple size in treatment studies targeted at reducing ven-
tilator dependence, a clinically meaningful primary
outcome.
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